MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools - 01/02/16

Doi : 10.1016/j.clinre.2015.10.001

Aitor Esparza-Baquer ^a,^{^{1
Both authors contributed equally to this work.}}, Ibone Labiano ^a,^{^{1
Both authors contributed equally to this work.}}, Luis Bujanda ^a,^b, María J. Perugorria ^a,^b,^c, Jesús M. Banales ^a,^b,^c,^⁎
^a Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain
^b National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain
^c IKERBASQUE, Basque Foundation for Science, Bilbao, Spain

^⁎Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	13
Iconographies	2
Vidéos	0
Autres	0

Summary

Cholangiopathies are the group of diseases targeting the bile duct epithelial cells (i.e. cholangiocytes). These disorders arise from different etiologies and represent a current diagnostic, prognostic and therapeutic challenge. Different molecular mechanisms participate in the development and progression of each type of biliary disease. However, microRNA deregulation is a common central event occurring in all of them that plays a key role in their pathogenesis. MicroRNAs are highly stable small non-coding RNAs present in cells, extracellular microvesicles and biofluids, representing valuable diagnostic tools and potential targets for therapy. In the following sections, the most novel and significant discoveries in this field are summarized and their potential clinical value is highlighted.

Le texte complet de cet article est disponible en PDF.

Abbreviations : ADPKD, ADPLD, AE2, Akt, ALP, AMAs, ANAs, ARPKD, BA, CA19-9, CCA, Cdc25A, CEA, c-Myc, dCCA, EMT, FDA, FOG2, FOXA2, GSK-3β, iCCA, IL-6, IL6R, InsP₃R3, KPE, miRNAs, PBC, PBMCs, pCCA, PCK rat, PDCD4, 15-PGDH/HPGD, PLDs, PPP2R2B, PSC, PSMD10/Gankyrin, PTEN, PTPN14, qHSCs, RECK, RRV-BALB/c, SMAD4, STAT3, TIMP3, UDCA, UTR

Plan

Introduction

Fibro-inflammatory cholangiopathies

Primary biliary cholangitis (PBC)

Primary sclerosing cholangitis (PSC)

Biliary atresia (BA)

Polycystic liver diseases (PLDs)

Cholangiocarcinoma (CCA)

Concluding remarks

Disclosure of interest

Export

Vol 40 - N° 1

P. 15-27 - février 2016 Retour au numéro

Article précédent

TERT promoter mutations in primary liver tumors
Jean-Charles Nault, Jessica Zucman-Rossi

| Article suivant

Endoscopic “rescue” treatment for gastrointestinal perforations, anastomotic dehiscence and fistula
Emanuele Dabizzi, Antonella De Ceglie, Kondal R. Kyanam Kabir Baig, Todd H. Baron, Massimo Conio, Michael B. Wallace

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

MicroRNAs in cholangiopathies: Potential diagnostic and therapeutic tools - 01/02/16

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL